Related references
Note: Only part of the references are listed.Impact of ferric carboxymaltose for iron deficiency at discharge after heart failure hospitalization: a European multinational economic evaluation
Phil McEwan et al.
EUROPEAN JOURNAL OF HEART FAILURE (2023)
Combining Iron Supplements With SGLT2 Inhibitor- Stimulated Erythropoiesis in Heart Failure: Should We Be Worried About Thromboembolic Events?
Milton Packer et al.
JOURNAL OF CARDIAC FAILURE (2023)
Increases in Fibroblast Growth Factor 23 During Treatment With Ferric Carboxymaltose: Potential Adverse Effects on the Heart and Kidneys
Milton Packer
JOURNAL OF CARDIAC FAILURE (2023)
Clinical and economic impact of ferric carboxymaltose treatment for iron deficiency in patients stabilized following acute heart failure: a multinational study
Phil McEwan et al.
JOURNAL OF MEDICAL ECONOMICS (2023)
Potential Interactions When Prescribing SGLT2 Inhibitors and Intravenous Iron in Combination in Heart Failure
Milton Packer
JACC-HEART FAILURE (2023)
Association Between Hemoglobin Levels and Efficacy of Intravenous Ferric Carboxymaltose in Patients With Acute Heart Failure and Iron Deficiency: An AFFIRM-AHF Subgroup Analysis
Gerasimos Filippatos et al.
CIRCULATION (2023)
Iron deficiency in pulmonary vascular disease: pathophysiological and clinical implications
Pieter Martens et al.
EUROPEAN HEART JOURNAL (2023)
Iron deficiency and cardiovascular disease
Gianluigi Savarese et al.
EUROPEAN HEART JOURNAL (2023)
Effect of intravenous iron replacement on recurrent heart failure hospitalizations and cardiovascular mortality in patients with heart failure and iron deficiency: a Bayesian meta-analysis
Stefan D. Anker et al.
EUROPEAN JOURNAL OF HEART FAILURE (2023)
Magnetic resonance imaging of organ iron before and after correction of iron deficiency in patients with heart failure
Christoph Gertler et al.
ESC HEART FAILURE (2023)
Micronutrient deficiencies in heart failure: Mitochondrial dysfunction as a common pathophysiological mechanism?
Nils Bomer et al.
JOURNAL OF INTERNAL MEDICINE (2022)
Iron Deficiency in Heart Failure: Mechanisms and Pathophysiology
Ridha I. S. Alnuwaysir et al.
JOURNAL OF CLINICAL MEDICINE (2022)
Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN) : an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial
Paul R. Kalra et al.
LANCET (2022)
Impact of ischaemic aetiology on the efficacy of intravenous ferric carboxymaltose in patients with iron deficiency and acute heart failure: insights from the AFFIRM-AHF trial
Marco Metra et al.
EUROPEAN JOURNAL OF HEART FAILURE (2022)
Rationale and design of a randomised trial of intravenous iron in patients with heart failure
Paul R. Kalra et al.
HEART (2022)
Iron Deficiency and Deranged Myocardial Energetics in Heart Failure
Michal Tkaczyszyn et al.
INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH (2022)
Intravenous iron: do we adequately understand the short- and long-term risks in clinical practice?
Deborah Rund
BRITISH JOURNAL OF HAEMATOLOGY (2021)
Oral sucrosomial iron improves exercise capacity and quality of life in heart failure with reduced ejection fraction and iron deficiency: a non-randomized, open-label, proof-of-concept study
Apostolos Karavidas et al.
EUROPEAN JOURNAL OF HEART FAILURE (2021)
Hospital readmissions of patients with heart failure from real world: timing and associated risk factors
Maria Wideqvist et al.
ESC HEART FAILURE (2021)
Iron deficiency in heart failure
Goran Loncar et al.
ESC HEART FAILURE (2021)
Relevance of nutritional assessment and treatment to counteract cardiac cachexia and sarcopenia in chronic heart failure
Antia Fernandez-Pombo et al.
CLINICAL NUTRITION (2021)
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Theresa A. McDonagh et al.
EUROPEAN HEART JOURNAL (2021)
Ferric carboxymaltose for the treatment of iron deficiency in heart failure: a multinational cost-effectiveness analysis utilising AFFIRM-AHF
Phil McEwan et al.
EUROPEAN JOURNAL OF HEART FAILURE (2021)
Iron Deficiency in Chronic Kidney Disease: Updates on Pathophysiology, Diagnosis, and Treatment
Elizabeth Katherine Batchelor et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2020)
Intravenous iron: a framework for changing the management of iron deficiency
Michael Auerbach et al.
Lancet Haematology (2020)
Intravenous iron supplementation therapy
Benedikt Schaefer et al.
MOLECULAR ASPECTS OF MEDICINE (2020)
Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial
Piotr Ponikowski et al.
LANCET (2020)
Effect of Iron Isomaltoside on Skeletal Muscle Energetics in Patients With Chronic Heart Failure and Iron Deficiency: FERRIC-HF II Randomized Mechanistic Trial
Geoffrey Charles-Edwards et al.
CIRCULATION (2019)
Intravenous iron therapy in heart failure: a different perspective
Kambiz Ghafourian et al.
EUROPEAN JOURNAL OF HEART FAILURE (2019)
Novel Oral Iron Therapies for Iron Deficiency Anemia in Chronic Kidney Disease
Pablo E. Pergola et al.
ADVANCES IN CHRONIC KIDNEY DISEASE (2019)
Hepatorenal dysfunction identifies high-risk patients with acute heart failure: insights from the RELAX-AHF trial
Jan Biegus et al.
ESC HEART FAILURE (2019)
Micronutrient Depletion in Heart Failure: Common, Clinically Relevant and Treatable
Natasa Cvetinovic et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Structural and functional abnormalities in iron-depleted heart
Kamil A. Kobak et al.
HEART FAILURE REVIEWS (2019)
Iron Deficiency in Heart Failure An Overview
Stephan von Haehling et al.
JACC-HEART FAILURE (2019)
Elevated lactate in acute heart failure patients with intracellular iron deficiency as an identifier of poor outcome
Jan Biegus et al.
KARDIOLOGIA POLSKA (2019)
Parenteral versus oral iron therapy for adults and children with chronic kidney disease
Emma L. O'Lone et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2019)
Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient data meta-analysis
Stefan D. Anker et al.
EUROPEAN JOURNAL OF HEART FAILURE (2018)
Myocardial iron content and mitochondrial function in human heart failure: a direct tissue analysis
Vojtech Melenovsky et al.
EUROPEAN JOURNAL OF HEART FAILURE (2017)
The available intravenous iron formulations: History, efficacy, and toxicology
Michael Auerbach et al.
HEMODIALYSIS INTERNATIONAL (2017)
Effect of Oral Iron Repletion on Exercise Capacity in Patients With Heart Failure With Reduced Ejection Fraction and Iron Deficiency The IRONOUT HF Randomized Clinical Trial
Gregory D. Lewis et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
Impaired hepato-renal function defined by the MELD XI score as prognosticator in acute heart failure
Jan Biegus et al.
EUROPEAN JOURNAL OF HEART FAILURE (2016)
Effects of intravenous iron therapy in iron-deficient patients with systolic heart failure: a meta-analysis of randomized controlled trials
Ewa A. Jankowska et al.
EUROPEAN JOURNAL OF HEART FAILURE (2016)
Iron therapy for the treatment of iron deficiency in chronic heart failure: intravenous or oral?
Theresa McDonagh et al.
EUROPEAN JOURNAL OF HEART FAILURE (2015)
Iron status in patients with chronic heart failure
Ewa A. Jankowska et al.
EUROPEAN HEART JOURNAL (2013)
Targeting the hepcidin-ferroportin axis to develop new treatment strategies for anemia of chronic disease and anemia of inflammation
Chia Chi Sun et al.
AMERICAN JOURNAL OF HEMATOLOGY (2012)
Micronutrient Deficiencies An Unmet Need in Heart Failure
Victor Soukoulis et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2009)
The emerging role of the gut in chronic heart failure
Anja Sandek et al.
CURRENT OPINION IN CLINICAL NUTRITION AND METABOLIC CARE (2008)
Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency
Darlington O. Okonko et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2008)
Intravenous iron reduces NT-Pro-Brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency
Jorge Eduardo Toblli et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2007)
Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein
E Nemeth et al.
BLOOD (2003)